At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 99 enrolled
Drug / intervention
TAK-850 0.5 mL injection +1 moredrug
Likely dose
TAK-850 0.5 mL injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center, Phase 1/2 Study to Evaluate the Safety and Immunogenicity of an Intramuscular Injection of TAK-850 in Healthy Pediatric Subjects
In Brief
A Phase 2 clinical trial evaluating TAK-850 0.5 mL injection and TAK-850 0.25 mL injection for Influenza Infection. Completed, enrolled 99 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity of an intramuscular injection of TAK-850 in healthy pediatric Japanese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza Infection
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
First PostedFeb 2015
Primary CompletionMay 2015
TodayJul 2026
First PostedFeb 20, 2015
Enrollment StartFeb 1, 2015
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.4 years ago
Interventions
TAK-850 0.5 mL injectiondrug
TAK-850 injection
TAK-850 0.25 mL injectiondrug
TAK-850 intramuscular injection